• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Thera (NQ: AXSM )

    88.84 -0.19 (-0.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Axsome Thera

    < Previous 1 2 3 4 5 Next >
    Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
    Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders 
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
    FDA sets PDUFA action goal date of January 31, 2025 
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Participate in Investor Conferences in September
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
    Via PressReach
    Exposures Product Safety
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
    EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures Product Safety
    Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
    From FN Media Group LLC
    Via GlobeNewswire
    Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
    Data on solriamfetol featured in two oral plenary sessions 
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Present at Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Recognizes May as Mental Health Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.